- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ashfield and IPCAA Study Reveals HCPs’ Thoughts On Virtual Congresses
Ashfield and IPCAA join forces to find out what HCPs really think about virtual medical congresses in new global study.
Ashfield Meetings & Events (part of UDG Healthcare PLC) and the International Pharmaceutical Congress Advisory Association (IPCAA) today released a study which reveals what healthcare professionals really think about virtual medical congresses.
Through a survey of more than 300 physicians from six countries (US and EU) and across 14 therapy areas, the global healthcare meetings specialist and the advisory association have gained detailed insights that are set to help medical societies, professional congress organizers (PCOs), and the industry consider how to shape virtual congresses of the future.
The study – the second part of which is planned for before the end of 2020 – looks at a variety of elements of the virtual congress, highlighting HCPs’ thoughts on accessibility and technology, how they viewed the online activities including industry symposia and poster sessions, and connecting with industry and peers.
For a summary report of IPCAA and Ashfield’s initial findings, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
